Skip to main content

Table 1 Baseline characteristics at randomisation

From: Can losartan and blood pressure control peri arteriovenous fistula creation ameliorate the early associated left ventricular hypertrophic response a randomised placebo controlled trial

Variable Losartan (n = 12) Placebo (n = 14)
Age (y) 66.5 (56–73) 57.5 (38.5–63)a
Gender (F: M) 4: 8 6: 8
eGFR 9.5 (6–16) 12 (10–14.5)
Hemoglobin 111.5 (104–128.5) 117 (111–138)
Creatinine 465 (322.5–597.3) 440 (339–480)
sSBP (mmHg) 1142 (132–160) 137 (130–153.5)
sDBP (mmHg) 74 (72–80) 78 (70–86)
sHR (bpm) 64 (60–74) 68 (61–74)
Weight (kg) 74.2 (71.4–88.3) 80 (70–89.4)
BSA (kg/m2) 1.90 (1.76–2.10) 1.91 (1.79–2.06)
BNP (ng/L) 285 (65–1194) 163 (63–303.3)
Additional antihypertensive medications (n) (non protocol) 2.0 (0.5–2.5) 2.0 (0–3)
  1. This table shows the gender spread, age, estimated glomerular filtration rate (eGFR), sitting (s) systolic (SBP), diastolic blood pressure (DBP) and heart rate (HR), weight and body surface area (BSA), brain natriuretic peptide (BNP) measurement and the additional number of antihypertensive medications (excluding protocol medications) in the atenolol plus losartan (losartan) and atenolol plus placebo (placebo) groups. Data is expressed as median (interquartile range) other than for gender, which is expressed as a ratio. Statistical comparison was undertaken by the Mann–Whitney U test. Comparison of the gender spread was undertaken with a Chi square test. Statistically significant differences are marked by the letter a (a). (Please note: non protocol medications with an antihypertensive effect included: calcium channel blockers, diuretics, prazosin, glyceryl trinitrate patch and moxonidine).